Risankizumab for Healthy Subjects
Trial Summary
What is the purpose of this trial?
This study will assess the pharmacokinetics, relative bioavailability and tolerability of two formulations of risankizumab following subcutaneous (SC) administration in healthy adult participants.
Research Team
ABBVIE INC.
Principal Investigator
AbbVie
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of one of three formulations of Risankizumab on day 1
Follow-up
Participants are monitored for pharmacokinetics, relative bioavailability, and tolerability, with assessments up to day 140
Treatment Details
Interventions
- Risankizumab
Risankizumab is already approved in Canada, United States, European Union for the following indications:
- Moderate-to-severe Crohn's disease
- Moderate-to-severe Crohn's disease
- Moderate-to-severe plaque psoriasis
- Moderate-to-severe Crohn's disease
- Moderate-to-severe plaque psoriasis
- Psoriatic arthritis
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois